NAC for Attenuation of COVID-19 Symptomatology

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cambridge Health Alliance
• Collaborators: Alturix; The Thoracic Foundation
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• positive COVID test <= 7 days of enrollment

Exclusion Criteria:

• pregnant

• already hospitalized due to COVID